

Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

### Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

[Submit a Proposal](#)

[Contact Us](#)

## New Manuscript Highlights ARLG Achievements and 2.0 Scientific Agenda

Health organizations such as the [Centers for Disease Control \(CDC\)](#) and the [National Institute of Allergy and Infectious Diseases \(NIAID\)](#) continue to sound the alarm over the ongoing global threat of antibacterial resistance. A new manuscript published in [Clinical Infectious Diseases](#) details how renewed funding of more than \$100 million from the NIAID enables a network of more than 100 infectious diseases experts with the Antibacterial Resistance Leadership Group (ARLG) to prioritize, design, and execute innovative clinical research to combat antibacterial resistance.

The manuscript, “Antibacterial Resistance Leadership 2.0 – Back to Business”, updates the scientific community on the accomplishments facilitated by ARLG’s initial 2013 grant and outlines how the research agenda for the seven-year, competitive renewal [awarded](#) in December 2019 is addressing the antibacterial resistance crisis.

The [Duke Clinical Research Institute](#) serves as the operational coordinating center for the ARLG network, which has initiated more than 55 studies in 19 countries, and has published more than 155 manuscripts. The updated agenda prioritizes the execution of clinical research that combines ARLG’s international networks, innovative study design, and strong operational structure while highlighting core values such as mentoring and

[Read More](#)

---

## ARLG Spotlight: Michael Satlin

### About my role in the ARLG

As an ARLG trialist in training, I receive funding, guidance, and mentorship that is allowing me to lead a multicenter study to identify the frequency and clinical significance of colonization with fluoroquinolone-resistant gut bacteria in neutropenic patients. In addition, ARLG has given me the opportunity to participate on the Gram-Negative Subcommittee and Immunocompromised Host Working Group where I can contribute to the development of other clinical trials.



Michael Satlin, MD, MS  
Assoc. Prof. of Medicine  
Assoc. Prof. of Pathology & Laboratory Medicine  
Clinical Director, Transplant-Oncology ID Program  
Weill Cornell Medicine

### About my research

Patients with hematologic malignancies are uniquely susceptible to life-threatening bloodstream infections from gram-negative gut bacteria when they are neutropenic after chemotherapy. The current standard-of-care is to administer fluoroquinolones prophylactically to prevent gram-negative infections during neutropenia. However, the rising rate of bacterial resistance to fluoroquinolone threatens the effectiveness of this approach.

Our study will determine the frequency of colonization with fluoroquinolone-resistant *Enterobacterales* in this patient population when they begin chemotherapy. We will also assess whether patients colonized with these bacteria are more likely to develop gram-negative bloodstream infections.

### Impact of ARLG mentoring and funding on my career


I am forever grateful that ARLG's mentorship and opportunities have allowed me to successfully launch my research career. Senior ARLG members helped to provide the preliminary data for the current study by serving on a Scientific Advisory Board to support my K23 Career Development Award. The mentorship guided my transition from the initial award all the way to becoming an independent investigator. The opportunity to network with leading clinical researchers in the field of antimicrobial resistance has also led to additional collaborative research and grant funding.

[Read More](#)

## News

---

### Thomas Holland Chosen as Presidential Award Team Winner



ARLG primary investigator, [Thomas L. Holland](#), MD, is being honored alongside [Cameron R. Wolfe](#), MBBS, and the Division of Infectious Diseases, all with Duke University Hospital, to receive the Presidential Award.

Holland, Wolfe, and members of their team were nominated for the award in recognition of their leadership and service efforts to combat the COVID-19 pandemic.

Thomas L. Holland, MD, MSc  
Associate Professor of Medicine  
Dept. of Medicine, Division of ID  
Duke University

[Read more](#)

---

### Tori Kinamon Awarded FDA ORISE Fellowship!

The Food and Drug Association (FDA) selected Air Force 2<sup>nd</sup> Lt. Tori Kinamon, MD Candidate at the [Duke University School of Medicine](#), to receive an FDA Antibacterial Drug Resistance (DOOR) Fellowship, which evaluates ordinal endpoints using the [Desirability of Outcome Ranking](#) (DOOR) approach for anti-infective clinical trials. The one year fellowship, which begins June 2021, is with the Office of Infectious Diseases Division of Anti-infectives led by Sumanthi Nambiar, MD.

[Read more](#)

---

## ARLG Early Stage Investigator Seed Grant Opportunities

As part of our mission to mentor the next generation of researchers and foster diversity, ARLG offers seed grant opportunities to help early stage investigators (ESI) develop preliminary data and apply for additional external funding.

**ESI Seed Grants** offer up to \$50,000 in direct costs for research in any area related to antibacterial resistance for up to five ESIs.

**Early Stage Investigator Program Promoting Diversity in Antibiotic Resistance Research (EVERYONE) Seed Grants** aim to foster diversity in the field of antibacterial resistance by offering up to \$50,000 in direct costs for research in any area related to antibacterial resistance for up to two EVERYONE investigators.

Individuals who are MD, PhD, or Pharm D students, graduate or post-graduate trainees, or those with a faculty appointment of less than five years are all eligible to apply.

[Read More](#)

### Events and Deadlines

---

#### Join ARLG Members at SHEA Spring 2021!

Be on the lookout for ARLG members at the [Society for Healthcare Epidemiology of America \(SHEA\) Spring 2021 Conference](#) which takes place from April 13-16. SHEA Spring 2021 features networking and mentorship opportunities, valuable workshops, abstract sessions, and conference sessions focused on a variety of infections and antibiotic resistance related topics. Though the event is virtual this year, SHEA Spring 2021 continues to connect participants with one another to learn and advance the fields of healthcare epidemiology and antibiotic stewardship.

[Learn more](#)



## WORLD MICROBE FORUM

20-24 JUNE 2021 | ONLINE WORLDWIDE

An American Society for Microbiology (ASM)  
and Federation of European Microbiological Societies (FEMS) Collaboration.

## World Microbe Forum 2021

The [American Society for Microbiology \(ASM\)](#) and the [Federation for European Microbiological Societies \(FEMS\)](#) have teamed up to bring you the World Microbe Forum happening online June 20 – 24.

Experts from around the world will offer insight and discuss solutions on topics such as infectious pathogens, agriculture and food microbiology, and the role of microbes in climate change.

**Abstract submission reopens April 23 and closes May 7!**

Learn more about the submission guidelines and how to register for the event.

[Register to Attend](#)

[Submit Your Abstract](#)

---

## ECCMID 2021 Late-breaking Abstract Deadline

The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) is coming up soon! From July 9 – 12, clinical microbiology and international infectious diseases experts will present their latest findings and information.

The event will take place in Vienna, Austria and online. There is still time to share your research or case report.

**Late-breaking abstracts will be accepted April 26 - May 7, 2021.**

Get more information about the guidelines and register for the event.

[Register to Attend](#)

[Submit Your Abstract](#)

---

## Connect at IDWeek 2021

Stay tuned! IDWeek 2021 will be here before you know it. This year's event will happen September 29-October 3, 2021 and will offer access to networking and collaborative opportunities with ARLG thought leaders and other experts in infectious diseases. The annual meeting will give participants a chance to learn from one another, while working to improve public health and patient care.

**Abstract submissions will be accepted until June 9, 2021.**

[Learn more](#)



### Study Milestones

View recent ARLG study updates.

**COMBINE**

AVYCAZ® in **COMBINATION**  
with Aztreonam

Database locked

---

**DOTS**

Dalbavancin as an **Option**  
for Treatment of *S. aureus*  
Bacteremia

Enrolling

---

**SCENE**

Screening for **Colonization**  
with Resistant  
Enterobacterales in  
Neutropenic Patients with  
Hematologic **Malignancies**

Enrolling (FPI)

---

**MDRO: SHREC**

MDRO: **Study of Highly**  
Resistant **Escherichia coli**

Enrollment 98% complete

Go to the ARLG Studies page for more milestones and updates!

[Learn More](#)



## Recent Publications

View the following recent ARLG publications.

Nematollahi S, Konold V, Gaston D, Howard-Anderson J, Kiley J, Masters MC, Melia MT, Balba GP, Chiang A, Gupta N. Impact of COVID-19 on Infectious Diseases Fellows in the United States: Perspectives from the First National ID Fellows Call . *Open Forum Infect Dis.* 2021 Jan 28;8(2):ofab021. doi: 10.1093/ofid/ofab021. eCollection 2021 Feb.

Howard-Anderson J, Adams C, Sherman AC, Dube WC, Smith TC, Edupuganti N, Chea N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg JP, Lopman BA, Jacob JT, Collins MH, Fridkin SK. Occupational Risk Factors for SARS-CoV-2 infection among Healthcare Personnel: A Cross-Sectional Analysis of Subjects Enrolled in the COPE Study. *Infect Control. Infect Control Hosp Epidemiol.* 2021Feb 9;1-20.doi: 10.1017/ice.2021.54.

**Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher H, van Duin D, Tsalik EL, Holland TL, Pettigrew M, Tamma P, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0 – Back to Business. *Clin Infect Dis.* 2021 Feb 15;ciab141. doi: 10.1093/cid/ciab141. Online ahead of print.**

**Lodise TP, Van Wart S, Sund ZM, Bressler AM, Khan A, Makley AT, Hamad Y, Salata RA, Silveira FP, Sims MD, Kabchi BA, Saad MA, Brown C, Oler RE Jr, Fowler V Jr, Wunderink RG. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multi-Center Study (ACUMIN). *Antimicrob Agents Chemother.* 2021 Feb 17;65(3):e01809-20.**

Queen J, Karaba S, Albin J, Karaba A, Howard-Anderson J, Platt L, Skinner N, Herman J, Paras ML, Melia MT. The Time is Now: A Call for Renewed Support of Infectious Disease Physician-Scientist Trainees in the COVID-19 Era. *J Infect Dis.* 2021 Mar 26;jjab162. doi: 10.1093/infdis/jjab162. Online ahead of print.